Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Identifieur interne : 001813 ( Main/Corpus ); précédent : 001812; suivant : 001814Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
Auteurs : John R. Giudicessi ; Peter A. Noseworthy ; Paul A. Friedman ; Michael J. AckermanSource :
- Mayo Clinic proceedings [ 1942-5546 ] ; 2020.
English descriptors
- KwdEn :
- Anti-Infective Agents (administration & dosage), Anti-Infective Agents (adverse effects), Betacoronavirus (drug effects), Betacoronavirus (isolation & purification), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Death, Sudden, Cardiac (etiology), Death, Sudden, Cardiac (prevention & control), Drug Combinations (MeSH), Drug Monitoring (methods), Drug Repositioning (ethics), Drug Repositioning (methods), Electrocardiography (methods), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Long QT Syndrome (chemically induced), Long QT Syndrome (mortality), Long QT Syndrome (therapy), Lopinavir (administration & dosage), Lopinavir (adverse effects), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Risk Adjustment (methods), Ritonavir (administration & dosage), Ritonavir (adverse effects), SARS-CoV-2 (MeSH), Torsades de Pointes (chemically induced), Torsades de Pointes (mortality), Torsades de Pointes (therapy).
- MESH :
- chemical , administration & dosage : Anti-Infective Agents, Hydroxychloroquine, Lopinavir, Ritonavir.
- chemical , adverse effects : Anti-Infective Agents, Hydroxychloroquine, Lopinavir, Ritonavir.
- chemically induced : Long QT Syndrome, Torsades de Pointes.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- ethics : Drug Repositioning.
- etiology : Death, Sudden, Cardiac.
- isolation & purification : Betacoronavirus.
- methods : Drug Monitoring, Drug Repositioning, Electrocardiography, Risk Adjustment.
- mortality : Long QT Syndrome, Torsades de Pointes.
- prevention & control : Death, Sudden, Cardiac.
- therapy : Long QT Syndrome, Torsades de Pointes.
- COVID-19, Drug Combinations, Humans, Pandemics, SARS-CoV-2.
Abstract
As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the "off-label" repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which have the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death. With the possibility that a considerable proportion of the world's population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.
DOI: 10.1016/j.mayocp.2020.03.024
PubMed: 32359771
PubMed Central: PMC7141471
Links to Exploration step
pubmed:32359771Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).</title><author><name sortKey="Giudicessi, John R" sort="Giudicessi, John R" uniqKey="Giudicessi J" first="John R" last="Giudicessi">John R. Giudicessi</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Clinician-Investigator Training Program, Mayo Clinic, Rochester, MN; Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Noseworthy, Peter A" sort="Noseworthy, Peter A" uniqKey="Noseworthy P" first="Peter A" last="Noseworthy">Peter A. Noseworthy</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Friedman, Paul A" sort="Friedman, Paul A" uniqKey="Friedman P" first="Paul A" last="Friedman">Paul A. Friedman</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Ackerman, Michael J" sort="Ackerman, Michael J" uniqKey="Ackerman M" first="Michael J" last="Ackerman">Michael J. Ackerman</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN; Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN; Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN. Electronic address: ackerman.michael@mayo.edu.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32359771</idno><idno type="pmid">32359771</idno><idno type="doi">10.1016/j.mayocp.2020.03.024</idno><idno type="pmc">PMC7141471</idno><idno type="wicri:Area/Main/Corpus">001813</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001813</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).</title><author><name sortKey="Giudicessi, John R" sort="Giudicessi, John R" uniqKey="Giudicessi J" first="John R" last="Giudicessi">John R. Giudicessi</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Clinician-Investigator Training Program, Mayo Clinic, Rochester, MN; Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Noseworthy, Peter A" sort="Noseworthy, Peter A" uniqKey="Noseworthy P" first="Peter A" last="Noseworthy">Peter A. Noseworthy</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Friedman, Paul A" sort="Friedman, Paul A" uniqKey="Friedman P" first="Paul A" last="Friedman">Paul A. Friedman</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN.</nlm:affiliation></affiliation></author><author><name sortKey="Ackerman, Michael J" sort="Ackerman, Michael J" uniqKey="Ackerman M" first="Michael J" last="Ackerman">Michael J. Ackerman</name><affiliation><nlm:affiliation>Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN; Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN; Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN. Electronic address: ackerman.michael@mayo.edu.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Mayo Clinic proceedings</title><idno type="eISSN">1942-5546</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Infective Agents (administration & dosage)</term><term>Anti-Infective Agents (adverse effects)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (isolation & purification)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Death, Sudden, Cardiac (etiology)</term><term>Death, Sudden, Cardiac (prevention & control)</term><term>Drug Combinations (MeSH)</term><term>Drug Monitoring (methods)</term><term>Drug Repositioning (ethics)</term><term>Drug Repositioning (methods)</term><term>Electrocardiography (methods)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (adverse effects)</term><term>Long QT Syndrome (chemically induced)</term><term>Long QT Syndrome (mortality)</term><term>Long QT Syndrome (therapy)</term><term>Lopinavir (administration & dosage)</term><term>Lopinavir (adverse effects)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>Risk Adjustment (methods)</term><term>Ritonavir (administration & dosage)</term><term>Ritonavir (adverse effects)</term><term>SARS-CoV-2 (MeSH)</term><term>Torsades de Pointes (chemically induced)</term><term>Torsades de Pointes (mortality)</term><term>Torsades de Pointes (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Infective Agents</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Infective Agents</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Long QT Syndrome</term><term>Torsades de Pointes</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="ethics" xml:lang="en"><term>Drug Repositioning</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Death, Sudden, Cardiac</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Monitoring</term><term>Drug Repositioning</term><term>Electrocardiography</term><term>Risk Adjustment</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Long QT Syndrome</term><term>Torsades de Pointes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Death, Sudden, Cardiac</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Long QT Syndrome</term><term>Torsades de Pointes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Drug Combinations</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the "off-label" repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which have the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death. With the possibility that a considerable proportion of the world's population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32359771</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1942-5546</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Mayo Clinic proceedings</Title><ISOAbbreviation>Mayo Clin Proc</ISOAbbreviation></Journal><ArticleTitle>Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).</ArticleTitle><Pagination><MedlinePgn>1213-1221</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0025-6196(20)30313-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mayocp.2020.03.024</ELocationID><Abstract><AbstractText>As the coronavirus disease 19 (COVID-19) global pandemic rages across the globe, the race to prevent and treat this deadly disease has led to the "off-label" repurposing of drugs such as hydroxychloroquine and lopinavir/ritonavir, which have the potential for unwanted QT-interval prolongation and a risk of drug-induced sudden cardiac death. With the possibility that a considerable proportion of the world's population soon could receive COVID-19 pharmacotherapies with torsadogenic potential for therapy or postexposure prophylaxis, this document serves to help health care professionals mitigate the risk of drug-induced ventricular arrhythmias while minimizing risk of COVID-19 exposure to personnel and conserving the limited supply of personal protective equipment.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giudicessi</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Clinician-Investigator Training Program, Mayo Clinic, Rochester, MN; Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noseworthy</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ackerman</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Division of Heart Rhythm Services, Mayo Clinic, Rochester, MN; Department of Pediatric and Adolescent Medicine, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN; Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN. Electronic address: ackerman.michael@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mayo Clin Proc</MedlineTA><NlmUniqueID>0405543</NlmUniqueID><ISSNLinking>0025-6196</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016757" MajorTopicYN="Y">Death, Sudden, Cardiac</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="Y">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008133" MajorTopicYN="Y">Long QT Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="Y">Lopinavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020379" MajorTopicYN="N">Risk Adjustment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016171" MajorTopicYN="Y">Torsades de Pointes</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32359771</ArticleId><ArticleId IdType="pii">S0025-6196(20)30313-X</ArticleId><ArticleId IdType="doi">10.1016/j.mayocp.2020.03.024</ArticleId><ArticleId IdType="pmc">PMC7141471</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2006 Sep 13;296(10):1249-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16968849</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2008 Apr 29;117(17):2184-91</Citation><ArticleIdList><ArticleId IdType="pubmed">18427136</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2008 Jul 4;127(2):e80-2</Citation><ArticleIdList><ArticleId IdType="pubmed">17590456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Apr;55(4):105932</Citation><ArticleIdList><ArticleId IdType="pubmed">32145363</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intern Med. 2006 Jan;259(1):59-69</Citation><ArticleIdList><ArticleId IdType="pubmed">16336514</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Clin (Barc). 2001 Jun 23;117(3):118-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11459586</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2004 Jan 19;484(1):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14729380</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS. 2011 Jan 28;25(3):367-77</Citation><ArticleIdList><ArticleId IdType="pubmed">21150558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 2013 Apr;88(4):315-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23541006</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Toxicol (Phila). 2006;44(2):173-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16615675</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2018 Apr 21;39(16):1466-1480</Citation><ArticleIdList><ArticleId IdType="pubmed">28329355</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2018 Nov 20;138(21):2345-2358</Citation><ArticleIdList><ArticleId IdType="pubmed">30571576</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2007 Jan 23;49(3):329-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17239714</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulation. 2019 Jun 11;139(24):2711-2713</Citation><ArticleIdList><ArticleId IdType="pubmed">31180747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurogastroenterol Motil. 2018 Jun;30(6):e13302</Citation><ArticleIdList><ArticleId IdType="pubmed">29441683</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2004 Sep;31(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15288617</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleve Clin J Med. 2013 Sep;80(9):539-44</Citation><ArticleIdList><ArticleId IdType="pubmed">24001961</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Electrophysiol. 2016 Jul;27(7):827-32</Citation><ArticleIdList><ArticleId IdType="pubmed">27027653</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001813 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001813 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32359771
|texte= Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32359771" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |